Syntaxin Biotechnology

Syntaxin expands its team with the appointment of Chief Medical Officer and Head of Cell Biology

Syntaxin’s new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry.

Syntaxin is delighted to announce that it has secured £16 million investment as part of Series B fundraising to help advance the biologics product pipeline towards clinical proof of the novel drugs' mechanism.

Syntaxin are proud to announce the re-launch of their website and brand with a new, fresh look which represents their status as industry leaders.

Syntaxin have appointed Philip Boyd as Chief Financial Officer. Philip joins Syntaxin from Evotec AG, where he was Senior Vice President, Finance and UK Finance Director.

Syntaxin have entered into a second exclusive research and license arrangement with Allergan to design and develop novel clostridial endopeptidase-based compounds.

Patrick James Doyle joins Syntaxin as Chief Executive Officer. Previously he was Chief Corporate Development Officer at Metabolex, California.

Syntaxin Ltd have been awarded a collaborative R&D grant of over £1.2million from the UK Department of Trade and Industry.

Syntaxin have been launched for the discovery and development of new treatments for neurological, respiratory and metabolic diseases.